
Aharon G Freud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/519712/publications.pdf Version: 2024-02-01



AHADON C EDELLD

#	Article	IF	CITATIONS
1	Gut dysbiosis is associated with acceleration of lupus nephritis. Scientific Reports, 2022, 12, 152.	3.3	17
2	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. Blood Cancer Discovery, 2022, 3, 154-169.	5.0	8
3	Clinical outcomes in Tâ€cell large granular lymphocytic leukaemia: prognostic factors and treatment response. British Journal of Haematology, 2021, 192, 484-493.	2.5	6
4	Established and emergent roles for Ikaros transcription factors in lymphoid cell development and function. Immunological Reviews, 2021, 300, 82-99.	6.0	26
5	Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia. Cancers, 2021, 13, 320.	3.7	6
6	Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy. JTO Clinical and Research Reports, 2021, 2, 100164.	1.1	6
7	Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	50
8	Differential Integrin Adhesome Expression Defines Human NK Cell Residency and Developmental Stage. Journal of Immunology, 2021, 207, 950-965.	0.8	9
9	Acute Myeloid Leukemia Alters Group 1 Innate Lymphoid Cell Differentiation from a Common Precursor. Journal of Immunology, 2021, 207, 1672-1682.	0.8	6
10	CD200R1 Distinguishes Uncommitted Precursors from Functionally Mature NK Cells within the Human Tonsil Stage 4A NK Cell Population. Blood, 2021, 138, 993-993.	1.4	0
11	EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia. Clinical Cancer Research, 2020, 26, 669-678.	7.0	18
12	Notch Regulates Innate Lymphoid Cell Plasticity during Human NK Cell Development. Journal of Immunology, 2020, 205, 2679-2693.	0.8	17
13	Editorial: Molecular and Cellular Pathways in NK Cell Development. Frontiers in Immunology, 2020, 11, 1448.	4.8	0
14	Research Autopsy Demonstrates Polyclonal Acquired Resistance in a Patient With Metastatic GI Stromal Tumor. JCO Precision Oncology, 2020, 4, 131-138.	3.0	3
15	Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Molecular Cancer Therapeutics, 2020, 19, 847-857.	4.1	91
16	MicroRNA regulation of natural killer cell development and function in leukemia. Molecular Immunology, 2019, 115, 12-20.	2.2	8
17	True Detective: Unraveling Group 1 Innate Lymphocyte Heterogeneity. Trends in Immunology, 2019, 40, 909-921.	6.8	50
18	Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 624-632.	3.9	5

Aharon G Freud

#	Article	IF	CITATIONS
19	Cellular pathways in the development of human and murine innate lymphoid cells. Current Opinion in Immunology, 2019, 56, 100-106.	5.5	54
20	Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy. Oncotarget, 2019, 10, 277-288.	1.8	6
21	Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leukemia and Lymphoma, 2018, 59, 1008-1011.	1.3	29
22	Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. Journal of Immunology, 2018, 200, 565-572.	0.8	33
23	SMAD4 promotes TGF-β–independent NK cell homeostasis and maturation and antitumor immunity. Journal of Clinical Investigation, 2018, 128, 5123-5136.	8.2	55
24	Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood, 2018, 132, 1792-1804.	1.4	66
25	CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity, 2018, 49, 464-476.e4.	14.3	86
26	Frequency and clinical correlates of elevated plasma Epsteinâ€Barr virus DNA at diagnosis in peripheral Tâ€cell lymphomas. International Journal of Cancer, 2017, 140, 1899-1906.	5.1	15
27	IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-κB. Journal of Immunology, 2017, 199, 2333-2342.	0.8	80
28	Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors. Journal of Molecular Diagnostics, 2017, 19, 682-696.	2.8	56
29	The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity, 2017, 47, 820-833.	14.3	485
30	Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells. Frontiers in Immunology, 2017, 8, 360.	4.8	112
31	Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). Discovery Medicine, 2017, 23, 189-199.	0.5	14
32	NKp80 Defines a Critical Step during Human Natural Killer Cell Development. Cell Reports, 2016, 16, 379-391.	6.4	100
33	A Progenitor Cell Expressing Transcription Factor RORÎ ³ t Generates All Human Innate Lymphoid Cell Subsets. Immunity, 2016, 44, 1140-1150.	14.3	153
34	Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S181-S190.e4.	0.4	7
35	Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. Current Hematologic Malignancy Reports, 2016, 11, 514-527.	2.3	149
36	MicroRNA-29b mediates altered innate immune development in acute leukemia. Journal of Clinical Investigation, 2016, 126, 4404-4416.	8.2	51

Aharon G Freud

#	Article	IF	CITATIONS
37	Biallelic mutations in IRF8 impair human NK cell maturation and function. Journal of Clinical Investigation, 2016, 127, 306-320.	8.2	76
38	Rapid Column-Free Enrichment of Mononuclear Cells from Solid Tissues. Scientific Reports, 2015, 5, 12490.	3.3	11
39	Transcription Factor Foxo1 Is a Negative Regulator of Natural Killer Cell Maturation and Function. Immunity, 2015, 42, 457-470.	14.3	141
40	Human natural killer cell development in secondary lymphoid tissues. Seminars in Immunology, 2014, 26, 132-137.	5.6	126
41	The Transcription Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells. Cell Reports, 2014, 8, 150-162.	6.4	84
42	Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. Human Pathology, 2014, 45, 1730-1736.	2.0	34
43	Location and cellular stages of natural killer cell development. Trends in Immunology, 2013, 34, 573-582.	6.8	288
44	Expression of the Activating Receptor, NKp46 (CD335), in Human Natural Killer and T-Cell Neoplasia. American Journal of Clinical Pathology, 2013, 140, 853-866.	0.7	36
45	Evidence for a stepwise program of extrathymic T cell development within the human tonsil. Journal of Clinical Investigation, 2012, 122, 1403-1415.	8.2	77
46	Interleukin-1β Selectively Expands and Sustains Interleukin-22+ Immature Human Natural Killer Cells in Secondary Lymphoid Tissue. Immunity, 2010, 32, 803-814.	14.3	180
47	In Vivo Role of Flt3 Ligand and Dendritic Cells in NK Cell Homeostasis. Journal of Immunology, 2010, 184, 2769-2775.	0.8	50
48	Purification of Human NK Cell Developmental Intermediates from Lymph Nodes and Tonsils. Methods in Molecular Biology, 2010, 612, 1-14.	0.9	11
49	Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH17 cytokine interleukin-22. Blood, 2009, 113, 4008-4010.	1.4	108
50	Human natural killer cell development. Immunological Reviews, 2006, 214, 56-72.	6.0	405
51	Evidence for discrete stages of human natural killer cell differentiation in vivo. Journal of Experimental Medicine, 2006, 203, 1033-1043.	8.5	370
52	A Human CD34(+) Subset Resides in Lymph Nodes and Differentiates into CD56brightNatural Killer Cells. Immunity, 2005, 22, 295-304.	14.3	331